Jaguar Animal Health Inc. (JAGX)
NASDAQ:JAGX
Top Page
Jaguar Animal Health
(NASDAQ:JAGX)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.66
▼(-48.67% Downside)
Action:ReiteratedDate:01/21/26
The score is held down primarily by weak financial performance (large ongoing losses, high leverage, and heavy cash burn) and a bearish technical setup (trading below all major moving averages with negative MACD). Corporate events provide a meaningful positive offset via non-dilutive funding and encouraging clinical progress, but not enough to overcome current financial and trend risks.
Positive Factors
High gross margins (~77% TTM)
Sustained ~77% gross margins indicate powerful unit economics for product sales. This margin profile can support investment in R&D and commercialization, absorb price or channel pressures, and materially improve profitability if fixed operating losses are reduced or revenue scales.
Negative Factors
Heavy operating cash burn
Persistent ~-$26M TTM cash burn is a structural drain that forces reliance on external financing or partnerships. Over 2–6 months this constrains ability to fund trials/commercial expansion, increases dilution risk, and may force unfavorable financing terms or asset sales absent material revenue or deal milestones.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins (~77% TTM)
Sustained ~77% gross margins indicate powerful unit economics for product sales. This margin profile can support investment in R&D and commercialization, absorb price or channel pressures, and materially improve profitability if fixed operating losses are reduced or revenue scales.
Read all positive factors
Jaguar Animal Health (JAGX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.47M
Dividend YieldN/A
Average Volume (3M)475.70K
Price to Earnings (P/E)―
Beta (1Y)2.23
Revenue Growth12.45%
EPS Growth-544.23%
CountryUS
Employees49
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.28
Shares Outstanding3,735,837
10 Day Avg. Volume368,153
30 Day Avg. Volume475,698
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.02
Price to Sales (P/S)0.64
P/FCF Ratio-0.25
Enterprise Value/Market Cap19.87
Enterprise Value/Revenue2.47
Enterprise Value/Gross Profit3.20
Enterprise Value/Ebitda-0.71
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.57
Revenue Forecast (FY)$14.87M
Jaguar Animal Health Business Overview & Revenue Model
Company Description
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two ...
How the Company Makes Money
Jaguar Animal Health generates revenue primarily through the sale of its pharmaceutical products and veterinary therapeutics. The company has established a revenue model that includes direct sales to veterinarians and animal health distributors, a...
Jaguar Animal Health Earnings Call Summary
Earnings Call Date:Aug 14, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Apr 06, 2026
Earnings Call Sentiment Neutral
The earnings call presented a positive outlook with significant revenue growth and successful clinical trial results for crofelemer, along with strategic regulatory advancements and expansion plans in the animal health market. However, these positive developments were offset by increased operational losses and net loss attributable to shareholders.Positive Updates
Significant Revenue Growth
The second quarter of 2025 saw a combined net revenue of approximately $3 million, representing a 35% increase compared to Q1 2025 and a 10% increase compared to Q2 2024.
Negative Updates
Increased Net Loss
Net loss attributable to common shareholders increased by approximately $900,000 from $9.5 million in Q2 2024 to $10.4 million in Q2 2025.
Read all updates
Q2-2025 Updates
Positive
Negative
Significant Revenue Growth
The second quarter of 2025 saw a combined net revenue of approximately $3 million, representing a 35% increase compared to Q1 2025 and a 10% increase compared to Q2 2024.
Read all positive updates
Company Guidance
During the earnings call for the second quarter of 2025, Jaguar Health reported a combined net revenue of approximately $3 million, marking a 35% increase compared to the first quarter of 2025 and a 10% increase compared to the second quarter of 2024. Mytesi prescription volume rose by 6.5% over the previous quarter. However, the company experienced a loss from operations of $8 million, an increase of $800,000 from the same period in 2024, and a net loss attributable to common shareholders of $10.4 million, up by $900,000. The non-GAAP recurring EBITDA showed a net loss reduction from $8.8 million in 2024 to $7.9 million in 2025. The financial guidance emphasized the importance of recent clinical and regulatory catalysts aiming to secure nondilutive funding and forge business development partnerships.Jaguar Animal Health Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.79M | 11.69M | 9.76M | 11.96M | 4.33M | 9.38M |
| Gross Profit | 9.09M | 9.73M | 7.72M | 9.94M | 2.00M | 6.11M |
| EBITDA | -41.16M | -36.66M | -32.76M | -33.38M | -42.37M | -28.74M |
| Net Income | -40.29M | -38.49M | -41.30M | -47.45M | -52.59M | -33.81M |
Balance Sheet | ||||||
| Total Assets | 49.47M | 53.42M | 50.76M | 47.45M | 53.27M | 42.84M |
| Cash, Cash Equivalents and Short-Term Investments | 3.53M | 8.00M | 6.47M | 5.47M | 17.05M | 8.09M |
| Total Debt | 31.90M | 36.53M | 37.09M | 34.84M | 29.36M | 16.21M |
| Total Liabilities | 45.11M | 46.93M | 45.87M | 48.81M | 41.41M | 25.64M |
| Stockholders Equity | 5.63M | 7.29M | 4.96M | -657.00K | 11.61M | 17.20M |
Cash Flow | ||||||
| Free Cash Flow | -26.08M | -29.61M | -33.24M | -34.78M | -34.98M | -15.29M |
| Operating Cash Flow | -26.02M | -29.38M | -33.24M | -33.10M | -34.97M | -15.28M |
| Investing Cash Flow | -269.00K | -231.00K | 0.00 | -1.68M | -6.00K | -7.00K |
| Financing Cash Flow | 16.71M | 31.20M | 34.23M | 23.18M | 43.94M | 19.49M |
Jaguar Animal Health Technical Analysis
Negative
1.28
Price Trends
0.64
Negative
0.97
Negative
1.62
Negative
Market Momentum
-0.08
Positive
34.28
Neutral
13.31
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JAGX, the sentiment is Negative. The current price of 1.28 is above the 20-day moving average (MA) of 0.53, above the 50-day MA of 0.64, and below the 200-day MA of 1.62, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 34.28 is Neutral, neither overbought nor oversold. The STOCH value of 13.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JAGX.
Jaguar Animal Health Risk Analysis
Jaguar Animal Health disclosed 65 risk factors in its most recent earnings report. Jaguar Animal Health reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
The growing use of AI systems to automate processes, analyze data, and support decision-making poses inherent risks. Q4, 2023
Jaguar Animal Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $3.68M | -0.59 | -212.63% | ― | 192.72% | 83.61% | |
45 Neutral | $1.47M | -0.09 | -710.57% | ― | 12.45% | -544.23% | |
44 Neutral | $3.22M | -1.00 | -46.34% | ― | ― | 70.71% | |
44 Neutral | $3.88M | ― | -203.36% | ― | ― | 90.53% | |
43 Neutral | $12.20M | -0.50 | -267.10% | ― | ― | 53.13% | |
42 Neutral | $4.20M | -2.23 | -0.40% | ― | ― | 96.26% |
* Healthcare Sector Average
JAGX
Jaguar Animal Health
0.34
-4.66
-93.16%
GLMD
Galmed Pharmaceuticals
0.50
-1.09
-68.30%
SNGX
Soligenix
1.13
-1.08
-48.87%
REVB
Revelation Biosciences
1.13
-31.27
-96.51%
DRMA
Dermata Therapeutics
1.37
-10.43
-88.39%
SXTP
60 Degrees Pharmaceuticals, Inc.
1.49
-5.87
-79.76%
Jaguar Animal Health Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Jaguar Health Executes Debt-Reducing Equity Warrant Transactions
Neutral
Jan 23, 2026
On January 16, 2026, Jaguar Health executed a series of privately negotiated exchanges with Iliad Research and Trading and Streeterville Capital that reduced outstanding royalty interests and retired portions of its Series L and Series M perpetual...
Business Operations and StrategyPrivate Placements and Financing
Jaguar Animal Health Grants U.S. Rights to Crofelemer Drugs
Positive
Jan 15, 2026
On January 12, 2026, Jaguar Health’s subsidiary Napo Pharmaceuticals entered into a U.S. licensing and supply arrangement with Woodward Specialty, an affiliate of Future Pak, under which Future Pak becomes the exclusive U.S. marketer of Jagu...
Private Placements and Financing
Jaguar Animal Health Raises Short-Term Capital Through Notes
Neutral
Jan 12, 2026
On January 6, 2026, Jaguar Health, Inc. entered into securities purchase agreements with two accredited investors and closed a financing in which it issued $350,000 in unsecured promissory notes bearing 6% annual interest and maturing one month af...
Business Operations and StrategyPrivate Placements and Financing
Jaguar Health Executes Strategic Stock Exchange Agreements
Neutral
Dec 12, 2025
On June 27, 2025, Jaguar Health, Inc. engaged in a transaction with Iliad Research and Trading, L.P., issuing 170 shares of Series M Perpetual Preferred Stock. Later, on December 9 and December 11, 2025, Jaguar Health entered into two separate exc...
Product-Related AnnouncementsShareholder Meetings
Jaguar Health Announces Promising Trial Results for Crofelemer
Positive
Dec 8, 2025
On December 8, 2025, Jaguar Health held a Special Meeting where stockholders approved three proposals, including the issuance of new shares and potential meeting adjournments. The company also announced promising initial results from a trial of cr...
Business Operations and StrategyPrivate Placements and Financing
Jaguar Health Amends Royalty Interests and Note Terms
Neutral
Nov 19, 2025
On November 17, 2025, Jaguar Health, Inc. announced amendments to its royalty interests with Iliad Research and Trading, Uptown Capital, and Streeterville Capital, setting a minimum monthly royalty payment starting April 1, 2026. Additionally, the...
Private Placements and Financing
Jaguar Animal Health Secures $10.8M Note Agreement
Neutral
Nov 14, 2025
On November 12, 2025, Jaguar Health, Inc. entered into a note purchase agreement with Streeterville Capital, LLC, issuing a secured promissory note worth $10,810,000. The agreement includes an original issue discount and legal fees, with funds all...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.